PMID- 23427858
OWN - NLM
STAT- MEDLINE
DCOM- 20131104
LR  - 20161125
IS  - 1879-1298 (Electronic)
IS  - 0045-6535 (Linking)
VI  - 91
IP  - 10
DP  - 2013 Jun
TI  - The flame-retardant BDE-99 dose-dependently affects viral replication in 
      CVB3-infected mice.
PG  - 1434-8
LID - S0045-6535(13)00138-0 [pii]
LID - 10.1016/j.chemosphere.2013.01.044 [doi]
AB  - The flame retardant component 2,2',4,4',5-penta-BDE (BDE-99) is found in the 
      environment and in human tissues and fluids. In mice the common human 
      coxsackievirus B3 (CVB3) infection has been shown to change the tissue 
      distribution of BDE-99. We now investigate how CVB3 infection in mice affects 
      liver uptake of (14)C at two doses of radiolabelled BDE-99, and whether increased 
      tissue levels are related to changed virus replication and gene expression of the 
      proinflammatory chemokine monocyte chemoattractant protein-1 (MCP-1). Mice were 
      infected on day 0, orally treated either with 200mug or 20mg (14)C-BDE-99/kgbw on 
      day 1, and euthanised on day 3. Serum and liver levels of (14)C-BDE-99, as well 
      as virus levels and gene expressions of MCP-1 in the liver, were measured. In 
      non-infected mice, there was a dose-dependent uptake of BDE-99 in both liver and 
      serum, and in infected animals the liver BDE-99 levels was further increased. 
      When comparing infected mice exposed to the two BDE-99 doses, the higher BDE dose 
      resulted in increased virus amounts in the liver, and decreased infection-induced 
      expression of MCP-1. Consequently, a high enough dose/tissue concentration of 
      BDE-99 may result in a disturbed mobilisation of immune cells into infected 
      tissues that could explain higher virus titres and a possibly altered clinical 
      course of the disease. Moreover, the fact that CVB3 infection increased the 
      BDE-99 levels in liver but not in serum may impair the risk assessment of 
      polybrominated diphenyl ethers (PBDEs) in subclinical and clinically infected 
      individuals, as serum levels is the common marker of exposure.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Lundgren, Magnus
AU  - Lundgren M
AD  - Risk Benefit Assessment Department, National Food Agency, Uppsala, Sweden.
FAU - Darnerud, Per Ola
AU  - Darnerud PO
FAU - Ilback, Nils-Gunnar
AU  - Ilback NG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130218
PL  - England
TA  - Chemosphere
JT  - Chemosphere
JID - 0320657
RN  - 0 (2,2',4,4',5-brominated diphenyl ether)
RN  - 0 (Carbon Radioisotopes)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Flame Retardants)
RN  - 0 (Halogenated Diphenyl Ethers)
SB  - IM
MH  - Animals
MH  - Carbon Radioisotopes
MH  - Chemokine CCL2/genetics
MH  - Coxsackievirus Infections/immunology/metabolism/*virology
MH  - Dose-Response Relationship, Drug
MH  - Enterovirus B, Human/*drug effects/physiology
MH  - Environmental Pollutants/pharmacokinetics/*toxicity
MH  - Female
MH  - Flame Retardants/pharmacokinetics/*toxicity
MH  - Gene Expression/drug effects
MH  - Halogenated Diphenyl Ethers/pharmacokinetics/*toxicity
MH  - Liver/diagnostic imaging/drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Radionuclide Imaging
MH  - Real-Time Polymerase Chain Reaction
MH  - Virus Replication/*drug effects
EDAT- 2013/02/23 06:00
MHDA- 2013/11/05 06:00
CRDT- 2013/02/23 06:00
PHST- 2012/06/07 00:00 [received]
PHST- 2012/11/22 00:00 [revised]
PHST- 2013/01/16 00:00 [accepted]
PHST- 2013/02/23 06:00 [entrez]
PHST- 2013/02/23 06:00 [pubmed]
PHST- 2013/11/05 06:00 [medline]
AID - S0045-6535(13)00138-0 [pii]
AID - 10.1016/j.chemosphere.2013.01.044 [doi]
PST - ppublish
SO  - Chemosphere. 2013 Jun;91(10):1434-8. doi: 10.1016/j.chemosphere.2013.01.044. Epub 
      2013 Feb 18.